Drugs / DA-5515
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03542721 | Jan 2018 → Jun 2019 | myalgic encephalomeyelitis/chronic fatigue syndrome | Dong-A Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-5515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03542721 ↗ |